Table 3.
Prevalence of AIDs in control individuals and individuals with type 1 diabetes at inclusion in study or onset of diabetes, respectively
| AID | Control individuals | Individuals with T1D | ||||
|---|---|---|---|---|---|---|
| Overall | Female individuals | Male individuals | Overall | Female individuals | Male individuals | |
| n | 74,210 | 33,085 | 41,125 | 15,188 | 6774 | 8414 |
| Coeliac disease | 387 (0.5) | 217 (0.7) | 170 (0.4) | 274 (1.8) | 150 (2.2) | 124 (1.5) |
| Thyroid disease | 129 (0.2) | 70 (0.2) | 59 (0.1) | 88 (0.6) | 50 (0.7) | 38 (0.5) |
| Psoriasis | 119 (0.2) | 50 (0.2) | 69 (0.2) | 26 (0.2) | 11 (0.2) | 15 (0.2) |
| Vitiligo | 51 (0.1) | 31 (0.1) | 20 (0.0) | 25 (0.2) | 11 (0.2) | 14 (0.2) |
| Rheumatic joint disease | 139 (0.2) | 82 (0.2) | 57 (0.1) | 34 (0.2) | 20 (0.3) | 14 (0.2) |
| Inflammatory bowel disease | 75 (0.1) | 34 (0.1) | 41 (0.1) | 20 (0.1) | 4 (0.1) | 16 (0.2) |
| SCTD | 147 (0.2) | 65 (0.2) | 82 (0.2) | 29 (0.2) | 14 (0.2) | 15 (0.2) |
| Uveitis | 51 (0.1) | 28 (0.1) | 23 (0.1) | 11 (0.1) | 5 (0.1) | 6 (0.1) |
| Addison’s disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (0.0) | 0 (0.0) | 2 (0.0) |
| Multiple sclerosis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Inflammatory liver disease | 1 (0.0) | 0 (0.0) | 1 (0.0) | 1 (0.0) | 0 (0.0) | 1 (0.0) |
| Atrophic gastritis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total number of autoimmune diagnoses | 1099 | 577 | 522 | 510 | 265 | 245 |
Data are shown as n (%) or n
SCTD, systemic connective tissue disorder; T1D, type 1 diabetes